Invivyd (IVVD) Net Income towards Common Stockholders (QoQ) (2021 - 2025)
Invivyd (IVVD) Net Income towards Common Stockholders (QoQ) (2021 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Invivyd | 104.07 Mn | -122.62 Mn | 16.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.33% |
| Sep 30, 2025 | 23.18% |
| Jun 30, 2025 | 9.94% |
| Mar 31, 2025 | 7.57% |
| Dec 31, 2024 | 70.48% |
| Sep 30, 2024 | -26.30% |
| Jun 30, 2024 | 37.38% |
| Mar 31, 2024 | -4.04% |
| Dec 31, 2023 | -69.31% |
| Sep 30, 2023 | 17.07% |
| Jun 30, 2023 | -36.51% |
| Mar 31, 2023 | 17.82% |
| Dec 31, 2022 | 9.45% |
| Sep 30, 2022 | 8.95% |
| Jun 30, 2022 | 47.26% |
| Mar 31, 2022 | -33.67% |
| Dec 31, 2021 | -37.95% |
| Sep 30, 2021 | -35.15% |
| Jun 30, 2021 | -15.11% |